The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (III): Pharmacological Treatment.
10.5765/jkacap.2017.28.2.70
- Author:
Hyo Won KIM
1
;
Eunjoo KIM
;
Ji Hoon KIM
;
Jangho PARK
;
Geon Ho BAHN
;
Yeon Jung LEE
;
Kyungun JHUNG
;
Dongwon SHIN
Author Information
1. Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Publication Type:Controlled Clinical Trial ; Review
- Keywords:
Attention-deficit hyperactivity disorder;
Psychostimulant;
Non-stimulant;
Pharmacotherapy
- MeSH:
Advisory Committees;
Atomoxetine Hydrochloride;
Central Nervous System;
Drug Therapy;
Drug-Related Side Effects and Adverse Reactions;
Europe;
Korea;
Toxicology;
United States
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2017;28(2):70-83
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The objective of this review is the revision of the Korean practice parameters for the pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) based on the change in the diagnostic system from DSM-IV-TR to DSM-5 and psychopharmacological developments. For the evidence-based approach, the authors conducted a review of the literature, including controlled clinical trials, studies of the side effects of drugs, toxicology and meta-analyses from the United States and Europe, as well as recent research conducted in Korea. The review committee composed of Korean experts on ADHD reviewed the revised parameters. This revised version reveals how to use central nervous system psychostimulants, non-stimulants such as atomoxetine and alpha2 agonists, and other medication for ADHD, and how to manage the adverse effects of such medication. At the end of this revised version, the authors propose recommendations for the pharmacotherapy of ADHD.
